Omalizumab for pediatric asthma

Bibliography

• Townley RG, Horiba M. Airway hyperresponsiveness: a story of mice and men and cytokines. Clin Rev Allergy Immunol 2003;24(1):85-110
   PubMed Web of Science ®Google Scholar
• Gold DR, Wright R. Population disparities in asthma. Annu Rev Public Health 2005;26:89-113
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Schoendorf KC. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 2002;110:315-22
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87
   PubMed Web of Science ®Google Scholar
• Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009;14:1156-65
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005;83:548-54
   PubMed Web of Science ®Google Scholar
• Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95
   PubMed Web of Science ®Google Scholar
• DuBuske LM. IgE, allergic diseases, and omalizumab. Curr Pharm Des 2006;12:3929-44
   PubMed Web of Science ®Google Scholar
• Oliver JM, Tarleton CA, Gilmartin L, Reduced FϵRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010;151:275-84
   PubMed Web of Science ®Google Scholar
• Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997;9:80:5-13
   Google Scholar
• Boulet LP, Chapman KR, Cote J, Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34
   PubMed Web of Science ®Google Scholar
• Brownell J, Casale TB. Anti-IgE therapy. Immunol Allergy Clin North Am 2004;24:551-68, v
   PubMed Web of Science ®Google Scholar
• MacGlashan DW Jr, Bochner BS, Adelman DC, Down-regulation of FcϵRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Riario-Sforza GG, Current and future applications of the anti-IgE antibody omalizumab. Biologics 2008;2:67-73
   PubMedGoogle Scholar
• Kuhn R. Immunoglobulin E blockade in the treatment of asthma. Pharmacotherapy 2007;27:1412-24
   PubMed Web of Science ®Google Scholar
• Sechi S, Roller PP, Willette-Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem 1996;271:19256-63
   PubMed Web of Science ®Google Scholar
• Presta L, Shields R, O'Connell L, The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:26368-73
   PubMed Web of Science ®Google Scholar
• Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G. Severe asthma and the omalizumab option. Clin Mol Allergy 2008;6:4
   PubMedGoogle Scholar
• Segal M, Stokes JR, Casale TB. Anti-immunoglobulin E therapy. WAO J 2008;1(10):174-83
   Google Scholar
• Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother 2007;41:1397-410
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H, Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-8
   PubMed Web of Science ®Google Scholar
• Casale TB, Bernstein IL, Busse WW, Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
   PubMed Web of Science ®Google Scholar
• Marcus P. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 2006;129:466-74
   PubMed Web of Science ®Google Scholar
• Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007;21:403-10
   PubMed Web of Science ®Google Scholar
• Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005;303:81-91
   PubMed Web of Science ®Google Scholar
• Belliveau PP, Lahoz MR. Evaluation of omalizumab from a health plan perspective. J Manag Care Pharm 2005;11:735-45
   PubMedGoogle Scholar
• Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265-9
   PubMed Web of Science ®Google Scholar
• Marshall GD Jr, Sorkness CA. IgE-blocking therapy for difficult-to-treat asthma: a brief review. Manag Care 2004;13:45-50
   PubMedGoogle Scholar
• Rambasek TE, Lang DM, Kavuru MS. Omalizumab: where does it fit into current asthma management? Cleve Clin J Med 2004;71:251-61
   PubMed Web of Science ®Google Scholar
• Bootman JL, Crown WH, Luskin AT. Clinical and economic effects of suboptimally controlled asthma. Manag Care Interface 2004;17:31-6
   PubMedGoogle Scholar
• Bousquet J, Cabrera P, Berkman N, The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-86
   PubMed Web of Science ®Google Scholar
• Holgate S, Bousquet J, Wenzel S, Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233-40
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
   PubMed Web of Science ®Google Scholar
• Kulus M, Hebert J, Garcia E, Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 2010;26:1285-93
   PubMed Web of Science ®Google Scholar
• Dreyfus DH, Randolph CC. Characterization of anaphylactoid reaction to omalizumab. Annals of Allergy asthma and Immunol 2006;96(4):624-7
   PubMed Web of Science ®Google Scholar
• Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120:1378-81
   PubMed Web of Science ®Google Scholar
• Barry PJ, O'Mahony A, Finnegan C, O'Connor TM. Delayed allergic reactions to omalizumab: are patients reporting all cases? J Allergy Clin Immunol 2008;121:785-86; author reply 786
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
   PubMed Web of Science ®Google Scholar
• Cox LS. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol 2009;5:4
   PubMedGoogle Scholar
• Milgrom H, Berger W, Nayak A, Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-16
   PubMed Web of Science ®Google Scholar
• Boyer D, Vargas SO, Slattery D, Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 2006;118:e914-20
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss syndrome in patients treated with omalizumab. Chest 2009;136:507-18
   PubMed Web of Science ®Google Scholar
• Kamin W, Kopp MV, Erdnuess F, Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21:e160-5
   PubMed Web of Science ®Google Scholar
• Engelberg H. Endogenous heparin activity deficiency: the ‘missing link’ in atherogenesis? Atherosclerosis 2001;159:253-60
   PubMed Web of Science ®Google Scholar
• D'Amato G, Salzillo A, Piccolo A, A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther Clin Risk Manag 2007;3:613-19
   PubMedGoogle Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64:1728-36
   PubMed Web of Science ®Google Scholar
• Ghosh TK, Eis PS, Mullaney JM, Competitive, reversible, and potent antagonism of inositol 1,4,5-trisphosphate-activated calcium release by heparin. J Biol Chem 1988;263:11075-9
   PubMed Web of Science ®Google Scholar
• Chilvers ER, Challiss RA, Willcocks AL, Characterisation of stereospecific binding sites for inositol 1,4,5-trisphosphate in airway smooth muscle. Br J Pharmacol 1990;99:297-302
   PubMed Web of Science ®Google Scholar
• Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 1986;261:7372-9
   PubMed Web of Science ®Google Scholar
• Ahmed T, Abraham WM, D'Brot J. Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 1992;145:566-70
   PubMed Web of Science ®Google Scholar
• Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993;147:160-3
   PubMed Web of Science ®Google Scholar
• Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993;329:90-5
   PubMed Web of Science ®Google Scholar
• Akagi K, Townley RG. Spontaneous histamine release and histamine content in normal subjects and subjects with asthma. J Allergy Clin Immunol 1989;83:742-9
   PubMed Web of Science ®Google Scholar
• Davids H, Ahmed A, Oberholster A, Endogenous heparin levels in the controlled asthmatic patient. S Afr Med J 2010;100:307-8
   PubMed Web of Science ®Google Scholar
• Lasser EC, Simon RA, Lyon SG, Heparin-like anticoagulants in asthma. Allergy 1987;42:619-25
   PubMed Web of Science ®Google Scholar
• Yurt RW, Leid RW Jr, Spragg J, Austen KF. Immunologic release of heparin from purified rat peritoneal mast cells. J Immunol 1977;118:1201-7
   PubMed Web of Science ®Google Scholar
• Tanizaki Y, Sudo M, Kitani H, Release of heparin-like substance and histamine from basophilic leucocytes separated by counterflow centrifugation elutriation. Jpn J Med 1990;29:356-61
   PubMedGoogle Scholar
• Langer RD, Criqui MH, Feigelson HS, IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol 1996;49:203-9
   PubMed Web of Science ®Google Scholar
• Wladyslaw S. Endogenous heparin – a protective marker in patients with myocardial infarction. Coron Artery Dis 2002;13:423-6
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Sladek K, Szczerba A, Dropinski J. Serum immunoglobulin E response to myocardial infarction. Circulation 1988;77:1245-9
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Kunkel G, Kleine Tebbe J. Basophils histamine release decreases during omalizumab therapy in allergic asthmatics Int Arch Allergy Immonology 2008;146:66-70
   PubMed Web of Science ®Google Scholar